$NRBO +750% Potential Upside - ReversalNASDAQ:NRBO +750% Potential Upside - Reversal. It is squeezing almost a year. It is about time for reversal. With volume, it would run multi days.
Next report date
Report period
Q1 2024
EPS estimate
−1.10USD
Revenue estimate
—
−2.46USD
−12.47 MUSD
1.97 M
About NeuroBo Pharmaceuticals, Inc.
Sector
Industry
CEO
Hyung-Heon Kim
Website
Headquarters
Cambridge
Employees (FY)
8
Founded
2014
FIGI
BBG009YPPXR8
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
NRBO | Huge Gains Incoming | OversoldNeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with mode
NRBO Spike Catcher 101Here is NRBO since the violation of its major resistance is at a point of a massive breakout to the following targets. The recent volume within the load-zone is also indicating a bullish breakout to arrive.
NRBO 400% Upside Potential | Covid-19 TreatmentOn 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO
But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday?
Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-pa
$NRBO is gonna fall todayPupm&Dump trading strategy idea.
$NRBO is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $3,69;
stop-loss — $4,12;
take-profit — $2,83.
Do not view th
NRBO Technical Analysis 🧙NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing therapies for patients with diabetic neuropathy and Alzheimer's disease. Its product candidate comprises NB-01, which is primarily focused on the development of a treatment for
Interesting Bottom PlayLooks to have found a bottom around 4.8-5.2.
Huge volume spike a few days ago, someone big probably built a position ahead of news.
We'll see where this goes.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NRBO is 3.14 USD — it has increased by 2.61% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeuroBo Pharmaceuticals, Inc. stocks are traded under the ticker NRBO.
NeuroBo Pharmaceuticals, Inc. is going to release the next earnings report on May 21, 2024. Keep track of upcoming events with our Earnings Calendar.
NRBO stock is 4.67% volatile and has beta coefficient of 0.72. Check out the list of the most volatile stocks — is NeuroBo Pharmaceuticals, Inc. there?
NRBO earnings for the last quarter are −0.72 USD per share, whereas the estimation was −0.88 USD resulting in a 18.18% surprise. The estimated earnings for the next quarter are −0.79 USD per share. See more details about NeuroBo Pharmaceuticals, Inc. earnings.
Yes, you can track NeuroBo Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
NRBO stock has fallen by 10.03% compared to the previous week, the month change is a 26.46% fall, over the last year NeuroBo Pharmaceuticals, Inc. has showed a 43.69% decrease.
NRBO net income for the last quarter is −5.31 M USD, while the quarter before that showed −3.82 M USD of net income which accounts for −39.18% change. Track more NeuroBo Pharmaceuticals, Inc. financial stats to get the full picture.
Today NeuroBo Pharmaceuticals, Inc. has the market capitalization of 15.01 M, it has decreased by 8.24% over the last week.
No, NRBO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NRBO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeuroBo Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 8.00 employees. See our rating of the largest employees — is NeuroBo Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeuroBo Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeuroBo Pharmaceuticals, Inc. stock shows the sell signal. See more of NeuroBo Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NeuroBo Pharmaceuticals, Inc. future price: according to them, NRBO price has a max estimate of 48.00 USD and a min estimate of 25.00 USD. Read a more detailed NeuroBo Pharmaceuticals, Inc. forecast: see what analysts think of NeuroBo Pharmaceuticals, Inc. and suggest that you do with its stocks.